Martin H. Schuler, MD, of the University Hospital Essen, discusses in German findings from this phase II trial of epirubicin, oxaliplatin, and capecitabine with or without the antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ disease. (Abstract 614O)
Yung-Jue Bang, MD, PhD, of Seoul National University Hospital, discusses phase III study findings on olaparib and paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy. (Abstract LBA25)
Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses overall survival data on afatinib vs gefitinib in patients with EGFR mutation-positive non-small cell lung cancer. (Abstract LBA43)
Martin Reck, MD, PhD, of the LungenClinic, discusses study findings on pembrolizumab vs platinum-based chemotherapy as first-line therapy for advanced non-small cell lung cancer with a PD-L1 tumor proportion score ≥50%. (Abstract LBA8)
Heinz-Josef Lenz, MD, of the University of Southern California Norris Comprehensive Cancer Center, discusses the importance of tumor location, and its implications for treatment, in right-sided and left-sided metastatic colon cancer.
Matthew J. Ellis, PhD, MB, BCh, of the Baylor College of Medicine, discusses phase III study findings on fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced disease. (Abstract LBA14)
